PharmaCyte Biotech, Inc. PMCB
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.11M | 4.91M | 4.93M | 3.75M | 3.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.46M | 5.30M | 5.38M | 4.23M | 3.96M |
| Operating Income | -5.46M | -5.30M | -5.38M | -4.23M | -3.96M |
| Income Before Tax | -16.15M | -19.42M | -3.28M | -7.07M | -1.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.15 | -19.42 | -3.28 | -7.07 | -1.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.15M | -19.42M | -3.28M | -7.07M | -1.13M |
| EBIT | -5.46M | -5.30M | -5.38M | -4.23M | -3.96M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -45.65 | -58.78 | -20.03 | -25.15 | -5.65 |
| Normalized Basic EPS | -11.07 | -21.22 | -10.67 | -9.73 | -0.69 |
| EPS Diluted | -45.65 | -58.78 | -20.03 | -25.15 | -5.65 |
| Normalized Diluted EPS | -11.07 | -21.22 | -10.67 | -9.73 | -0.69 |
| Average Basic Shares Outstanding | 1.97M | 1.76M | 1.56M | 1.44M | 1.49M |
| Average Diluted Shares Outstanding | 1.97M | 1.76M | 1.56M | 1.44M | 1.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -2.04% | -1.27% | -4.96% | -0.87% | -- |